2019, Chronic Condition, Clinic and Individual

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2019

Chronic Condition

Clinic

Individual

Psychedelics – reasons for caution: Stacy Fischer, Brian Anderson, Theora Cimino

GeriPal

MARCH 9, 2023

FDA is considering approval, shifting away from Schedule I restrictions, paving the way for use in clinical practice. Potential use in palliative care , chronic pain , and for mood disorders is tantalizing. In our prior podcast with Ira Byock on psychedelics in 2019 we talked primarily about the potential of psychedelics.

Patient-Centered

Patient-Centered Community IT Medical

Drug Pricing Reform Gathers Steam (Part 1): White House Drug Pricing Plan Offers Laundry List of Existing Democrat Priorities

FDA Law

SEPTEMBER 13, 2021

A May 2019 CMS final rule that would have required drug TV advertisements to disclose the WAC of the drug was challenged by a group of pharmaceutical companies and vacated on statutory grounds by the D.C. Drug Price Negotiation to Benefit Medicare and Commercial Plans. Part D currently has no such cap.

Manufacturing

Manufacturing Supply Chain Patient-Centered Utilities

Primary Care Digest

Psychedelics – reasons for caution: Stacy Fischer, Brian Anderson, Theora Cimino

Drug Pricing Reform Gathers Steam (Part 1): White House Drug Pricing Plan Offers Laundry List of Existing Democrat Priorities

Stay Connected